LUIS GONZAGA
PAZ-ARES RODRÍGUEZ
Profesor titular de universidad
Centro de Investigación Biomédica en Red de Cáncer
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red de Cáncer (28)
2024
-
RET Fusion Testing in Patients With NSCLC: The RETING Study
JTO Clinical and Research Reports, Vol. 5, Núm. 4
2023
-
Aberrant Methylation of the Imprinted C19MC and MIR371-3 Clusters in Patients with Non-Small Cell Lung Cancer
Cancers, Vol. 15, Núm. 5
-
At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC
Nature Reviews Clinical Oncology, Vol. 20, Núm. 3, pp. 143-159
-
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial
The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86
-
Future Perspectives in the Second Line Therapeutic Setting for Non-Oncogene Addicted Non-Small-Cell Lung Cancer
Cancers, Vol. 15, Núm. 23
-
Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy
International Journal of Molecular Sciences, Vol. 24, Núm. 18
-
PTEN Loss Confers Resistance to Anti–PD-1 Therapy in Non–Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells
Cancer Research, Vol. 83, Núm. 15, pp. 2513-2526
-
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer
Nature Communications, Vol. 14, Núm. 1
-
Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models
International Journal of Molecular Sciences, Vol. 24, Núm. 16
2022
-
Adoptive tumor infiltrating lymphocyte transfer as personalized immunotherapy
International Review of Cell and Molecular Biology (Elsevier Inc.), pp. 163-192
-
Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer
Expert Opinion on Emerging Drugs, Vol. 27, Núm. 3, pp. 289-300
-
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA
Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800
-
Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism
Nature medicine, Vol. 28, Núm. 4, pp. 752-765
-
Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy
Nanoscale, Vol. 14, Núm. 22, pp. 8028-8040
-
YES1 Is a Druggable Oncogenic Target in SCLC
Journal of Thoracic Oncology, Vol. 17, Núm. 12, pp. 1387-1403
2021
-
An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad antitumor activity in humanized murine cancer models without toxicity
Clinical Cancer Research, Vol. 27, Núm. 11, pp. 3167-3177
-
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Cancer Medicine, Vol. 10, Núm. 17, pp. 5878-5888
2019
-
Antitumor activity of an engineered decoy receptor targeting CLCF1–CNTFR signaling in lung adenocarcinoma
Nature Medicine, Vol. 25, Núm. 11, pp. 1783-1795
-
Necitumumab for the treatment of advanced non-small-cell lung cancer
Future Oncology, Vol. 15, Núm. 7, pp. 705-716
2018
-
Aligning digital CD8
+
scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma
Histopathology, Vol. 72, Núm. 2, pp. 270-284